Furthermore, we found that Gas/alb was an accurate biomarker for liver disease severity outperforming sAxl, sAxl/alb, and Gas6, as it was not only increasing with fibrosis stage, but also with CPS, MELD, and HVPG, and was able to non-invasively detect CSPH. This evidence concerns the gene GAS6 and liver disorder.